Treatment Alert

  • Clozapine is licensed for use in treatment-resistant schizophrenic patients and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics24.

  • Clozapine is also indicated in psychotic disorders occurring during the course of Parkinson’s disease, in cases where standard treatment has failed15.

Leyden Delta B.V.

Unit 5, Chase Industrial Estate,



Tel: +31 (0)24 372 6272

Fax: + 31 (0)24 372 6270


Copyright © 2019 Leyden Delta BV All rights reserved.

 Date of preparation: October 2019

The content of  website is designed for
healthcare professionals only